Zhongqiu Xie

University of Virginia — United States

Medicine · Health Sciences

20h-index1.4kcitations50works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(10), RNA modifications and cancer(9), RNA Research and Splicing(7), Cancer-related molecular mechanisms research(5), Prostate Cancer Treatment and Research(5)

Publications50 total

A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma
Science Translational Medicine·2026
Effect of Shear Deformation and Temperature History on Crystal Transformation of Polyvinylidene Fluoride/Silica Composites: A Molecular Dynamics Study
Polymer Composites·2025
CytoSIP: an annotated structural atlas for interactions involving cytokines or cytokine receptors
Communications Biology·2024· 2 citedOpen Access
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3
npj Precision Oncology·2024· 25 citedOpen Access
Supplementary Text from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
2023Open Access
Data from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
2023Open Access
Supplementary Fiures from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
2023Open Access
Supplementary Fiures from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
2023Open Access
Supplementary Text from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
2023Open Access
Data from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
2023Open Access
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
Journal of Experimental & Clinical Cancer Research·2023· 37 citedOpen Access
A Novel Protein-Encoding Circular RNA CCDC7<sub>19-15</sub> Inhibits the Progression of Prostate Cancer by Up-Regulating FLRT3
SSRN Electronic Journal·2023Open Access
CD46 targeted <sup>212</sup> Pb alpha particle radioimmunotherapy for prostate cancer treatment
2022Open Access
Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
Cell & Bioscience·2022· 17 citedOpen Access
Rhabdomyosarcomas are oncogene addicted to the activation of AVIL
Proceedings of the National Academy of Sciences·2022· 8 citedOpen Access
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
Cancer Biology and Medicine·2021· 51 citedOpen Access
Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma
Frontiers in Cell and Developmental Biology·2021· 2 citedOpen Access
GADD45B Is a Potential Diagnostic and Therapeutic Target Gene in Chemotherapy-Resistant Prostate Cancer
Frontiers in Cell and Developmental Biology·2021· 58 citedOpen Access
The discovery of AVIL as a <i>bona fide</i> oncogene in glioblastoma
Molecular & Cellular Oncology·2020· 3 citedOpen Access
Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition
Oncogene·2020· 25 cited
page 1 of 3Next →

Frequent Co-authors

Fujun Qin(14), Hui Li(12), E.Z. Luo(10), Jianbin Xu(9), Qiong Wang(9), Huiling Yuan(7), Mercedeh Movassagh(7), Hong Park(7), Wendy L. Golden(7), I. H. Wilson(7), Xinrui Shi(6), Sandeep Singh(6), Yuemeng Jia(5), Hai Huang(5), Jeffrey Sklar(4), Hui Li(4), James W. Mandell(3), Lihua Zhao(3), Kaiwen Li(3), Shirong Peng(3)